Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment

Epilepsy Research

Volumn 108, Issue 5, 2014, Pages 891-901

  Manitpisitkul, Prasarn ^a   Curtin, Christopher R ^a   Shalayda, Kevin ^a   Wang, Shean Sheng ^a   Ford, Lisa ^a   Heald, Donald L ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

End stage renal disease; Epilepsy; Hepatic impairment; Renal impairment; Topiramate

Indexed keywords

TOPIRAMATE; ANTICONVULSIVE AGENT; CREATINE; FRUCTOSE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHILD PUGH SCORE; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY CLEARANCE; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; PARALLEL DESIGN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; AGING; ANALOGS AND DERIVATIVES; BLOOD; KIDNEY FAILURE, CHRONIC; LIVER DISEASES; MIDDLE AGED; RENAL REPLACEMENT THERAPY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; AGING; ANTICONVULSANTS; CREATINE; FEMALE; FRUCTOSE; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER DISEASES; MALE; MIDDLE AGED; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 84900481999     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2014.03.011     Document Type: Article

References (26)

1. Almeida L., Potgieter J.H., Maia J., Potgieter M.A., Mota F., Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur. J. Clin. Pharmacol. 2008, 64:267-273.
2. Britzi M., Perucca E., Soback S., Levy R.H., Fattore C., Crema F., Gatti G., Doose D.R., Maryanoff B.E., Bialer M. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia 2005, 46:378-384.
3. Brockmoller J., Thomsen T., Wittstock M., Coupez R., Lochs H., Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A B, and C): characterization by dynamic liver function tests. Clin. Pharmacol. Ther. 2005, 77:529-541.
4. The Liver and Portal Hypertension. The Major Problems in Clinical Surgery 1964, vol. 1. Saunders, Philadelphia, WB. C.G. Child (Ed.).
5. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
6. Doose D.R., Scott V.V., Margul B.L., Marriott T.B., Nayak R.K. Multiple-dose pharmacokinetics of topiramate in healthy male subjects. Epilepsia 1988, 29:662.
7. Doose D.R., Gisclon L.G., Stellar S.M., Riffits J.M., Hills J.F. The effect of food on the bioavailability of topiramate from 100- and 400-mg tablets in healthy male subjects. Epilepsia 1992, 33:105.
8. Doose D.R., Walker S.A., Gisclon L.G., Nayak R.K. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J. Clin. Pharmacol. 1996, 36:884-891.
9. Doose D.R., Larsson K.L., Natarajan J., Neto W. Comparative single-dose pharmacokinetics of topiramate in elderly versus young men and women. Epilepsia 1998, 39:56.
10. Easterling D.E., Zakszewski T., Moyer M.D., Margul B.L., Marriott T.B., Nayak R.K. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. Epilepsia 1988, 29:662.
11. Ijiri Y., Inoue T., Fukuda F., Suzuki K., Kobayashi T., Shibahara N., Takenaka H., Tanaka K. Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. Epilepsia 2004, 45:924-927.
12. KEPPRA Prescribing Information 2011, December, UCB, Inc., Smyrna, GA.
13. Lal R., Sukbuntherng J., Luo W., Chen D., Blumenthal R., Ho J., Cundy K.C. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. Clin. Ther. 2012, 34:201-213.
14. Maia J., Almeida L., Falcao A., Soares E., Mota F., Potgieter M.A., Potgieter J.H., Soares-da-Silva P. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int. J. Clin. Pharmacol. Ther. 2008, 46:119-130.
15. Munar M.Y., Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am. Fam. Physician 2007, 75:1487-1496.
16. Nayak R.K., Gisclon L.G., Curtin D.A., Benet L.Z. Estimation of the absolute bioavailability of topiramate in humans without intravenous data. J. Clin. Pharmacol. 1994, 34:1029.
17. Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol. Res. 1997, 35:241-256.
18. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol. 2006, 61:246-255.
19. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973, 60:646-649.
20. Randinitis E.J., Posvar E.L., Alvey C.W., Sedman A.J., Cook J.A., Bockbrader H.N. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J. Clin. Pharmacol. 2003, 43:277-283.
21. Riffitts J.M., Gisclon L.G., Stubbs R.J., Palmer M.E. A capillary gas chromatographic assay with nitrogen phosphorus detection for the quantification of topiramate in human plasma, urine and whole blood. J. Pharm. Biomed. Anal. 1999, 19:363-371.
22. Sachdeo R.C., Sachdeo S.K., Walker S.A., Kramer L.D., Nayak R.K., Doose D.R. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996, 37:774-780.
23. Shank R.P., Maryanoff B.E. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci. Ther. 2008, 14:120-142.
24. Topamax Prescribing Information 2012, October, Janssen Pharmaceuticals, Titusville, NJ.
25. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp. Gerontol. 2003, 38:843-853.
26. Zand L., McKian K.P., Qian Q. Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. Am. J. Med. 2010, 123:367-373.